Gaurab Chakrabarti
About
Detail
CEO/Co-Founder
United States
Résumé
Jobs
verified_user
0% verified
CEO/Co-FounderSolugenJan 2017 - Current (9 years 6 months)We reimagine chemical manufacturing with the power of biology. www.solugen.com- MD/PhDUT Southwestern Medical CenterDec 2010 - May 2017 (6 years 6 months)M.D./Ph.D. student in the laboratory of Dr. David Boothman, studying the role of reactive oxygen species (e.g. hydrogen peroxide) to aid development of novel therapeutic targets in pancreatic cancer.
Education
verified_user
0% verified
- SolugenY CombinatorJan 2017 - Dec 2017 (1 year)
- Doctor of Philosophy (Ph.D, Oncology and Cancer BiologyUT Southwestern Medical CenterJan 2012 - Dec 2015 (4 years)Doctoral student in the laboratory of Dr. David Boothman, studying the development of novel therapeutic targets for pancreatic cancer. Dissertation Title: NQO1 bioactivatable drugs at the interface of cancer metabolism and the DNA damage response
- Doctor of Medicine (M.D, Cancer Metabolism and Novel TherapeuticsUT Southwestern Medical CenterJan 2010 - Dec 2017 (8 years)
- Bachelor of Science (B.Sc, Neuroscience, Computational BiologyBrown UniversityJan 2006 - Dec 2010 (5 years)Honor's Thesis: Studies of rigidity sensing and cellular traction forces
Publications
verified_user
0% verified
- APlant-based Peroxide-Maker Solugen Raises $4.4m Seed Round from Y Combinator, Joe Montana’s VC, othersAgFunderJan 2017
- Hydrogen peroxide inhibition of bicupin oxalate oxidase.PLOS ONEJan 2017
- These Sustainably Produced Cleaning Wipes Herald A Manufacturing RevolutionForbesJan 2017
- BUsing DNA devices to track anticancer drug activityBiosensors and BioelectronicsJan 2016
- CLeveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase InhibitorsCancer CellJan 2016
- MNQO1-Mediated Tumor-Selective Lethality and Radiosensitization for Head and Neck CancerMolecular Cancer TherapeuticsJan 2016
- NTumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-laNatureNov 2015
- CTargeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ß-lapachoneCancer and MetabolismOct 2015
- RMutant KRAS associated malic enzyme 1 expression is a predictive marker for radiation therapy response in non-small cellRADIATION ONCOLOGYJul 2015
- CExpanding antitumor therapeutic windows by targeting cancer-specific nicotinamide adenine dinucleotide phosphate-biogeneClinical PharmacologyMar 2015Nicotinamide adenine dinucleotide phosphate (NADPH) biogenesis is an essential mechanism by which both normal and cancer cells maintain redox balance. While antitumor approaches to treat cancers through elevated reactive oxygen species (ROS) are not new ideas, depleting specific NADPH-biogenesis pathways that control recovery and repair pathways are novel, viable approaches to enhance cancer therapy. However, to elicit efficacious therapies exploiting NADPH-biogenic pathways, it is crucial to understand and specifically define the roles of NADPH-biogenesis pathways used by cancer cells for survival or recovery from cell stress. It is equally important to select NADPH-biogenic pathways that are expendable or not utilized in normal tissue to
- NNAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe anNature Publishing GroupJan 2015
- ATumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs inAntioxidants and Redox SignalingJul 2014
- UWhat is evaluation of hematuria by primary care physicians? Use of electronic medical records to assess practice patternUrologic OncologyFeb 2014
- Vertex's VX-765 holds promise for HIV treatmentThe Motley FoolJan 2014
- With Phase II Success, Amgen's Romosozumab Beats Standard of Care TreatmentThe Motley FoolJan 2014
- MIodine pills, Japan and ScienceMedTalksMar 2011